Kolmar Holdings Q1 2026 consolidated operating profit KRW 20.4B, significant improvement

Q1 2026 consolidated revenue KRW 1,519B, operating profit KRW 20.4B, net income KRW 39.8B (sharp increase vs FY2025: operating profit KRW 47.7B, net income KRW 11.1B)
Holding company standalone revenue KRW 14.2B, operating profit KRW 4.4B, net income KRW 11.8B
Strong performance from key subsidiaries (Kolmar Korea, Kolmar BNH, HK Inno.N)
K-Cab global expansion progressing; pipeline advances (JAK1 inhibitor Phase 2, GLP-1 obesity treatment Phase 3)
Restructuring completed: sale of Kolmask stake, transfer of H&G cosmetics business
Litigation risk: 5 plaintiff cases, 9 defendant cases (approx. KRW 10.6B aggregate); financial impact uncertain
R&D expenditure: KRW 28.1B (2.20% of revenue), continued investment